Health

That is the title of a new paper published in Future Oncology with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier. The abstract is below: Aim To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse…

What factors should a physician consider on whether to use a new medical innovation on a patient? Of course, the potential benefits and risk of the innovation to the patient matter most. But another factor could play a role in the physician’s decision: malpractice liability. Specifically, (i) is the use of the innovation more likely…

I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…

Discrete choice experiments quantify respondent preferences over different alternative treatments due to their attributes. DCE assume individuals are rational and do not pick dominated options (i.e., where one option is weakly better than another option across all attributes and strictly better than the option across at least one attribute). However, Johnson et al. (2019) finds…

Treating serious mental illness is not just a good thing to do for altruistic reasons. It also can improve health outcomes and reduce cost for those with comorbid physical conditions as well. Vincent Joralemon writes in Health Affairs Forefront regarding this issue. The article quotes Sherry Rais, CEO of Enthea: Ten percent of patients drive…